HER2+ Peptide Conjugated and Ph Responsive Polyethylene Glycol- Poly(lactic-Co-glycolic) Acid (PEG-PLGA) Nanoparticles Tested in Novel Transgenic Mouse Tumor Model
Doleyres Yasmine,Cao Zhengyi,Wang Su He,Ma Peter
DOI: https://doi.org/10.3389/conf.fbioe.2016.01.02731
IF: 5.7
2016-01-01
Frontiers in Bioengineering and Biotechnology
Abstract:Event Abstract Back to Event HER2+ peptide conjugated and pH responsive polyethylene glycol- poly(lactic-co-glycolic) acid (PEG-PLGA) nanoparticles tested in novel transgenic mouse tumor model Yasmine Doleyres1, Zhengyi Cao2, Su He Wang2 and Peter X. Ma1, 3, 4, 5 1 University of Michigan, Macromolecular Sciences and Engineering Program, United States 2 University of Michigan, Michigan Nanotechnology Institute for Medicine and Biological Sciences, United States 3 University of Michigan, Department of Biologic and Materials Science, United States 4 University of Michigan, Department of Biomedical Engineering, United States 5 University of Michigan, Department of Materials Science and Engineering, United States Breast cancer is known as the second leading cause of cancer deaths among women in the United States[1],[2]. Depending on the stage of the cancer, treatment generally includes surgery, radiation, and/ or chemotherapy[3]. The biggest drawbacks with these treatment options, however, is that surgery is invasive, while chemotherapy is systemic and critically affects patients as chemotherapeutic drugs kill both cancer cells and fast-growing healthy cells. Unfortunately, 20% of women cleared of the disease experience a recurrence within ten years of their initial treatment[1]. Targeted drug delivery is one way in which treatment could be improved and made more effective by targeting more of the intended and residual cancer cells following tumor removal, while sparing healthy cells. Polymeric nanoparticles can be functionalized with targeting modalities such as peptides[4][5]. This project aims to improve the delivery of chemotherapeutic drugs for the treatment of breast cancer by not only including a targeting peptide identified through phage display, but also a pH responsive linkage for more selectivity (as cancerous tumors are found to be more acidic compared to healthy tissues[6]-[8]). Finally, test these particles in a novel transgenic mouse tumor model, which has an intact immune system. Polyethylene glycol (PEG)-Poly(lactic-co-glycolic) acid (PLGA) nanoparticles have been fabricated and loaded with the chemotherapeutic drug Doxorubicin conjugated to the core of the particles[9]. Using thiol-ene click chemistry[10],[11], an eight amino acid targeting peptide was attached to the particles. This peptide was identified through phage display as being specific for the SKBR-3 human breast cancer cell line[12],[13], which overexpresses the HER2 gene[14]. Early in vitro experiments showed that the peptide was approximately twice as effective at targeting and killing SKBR-3 cells compared to a control cell line. The particles were then tested in a mouse breast cancer model for human HER2+ breast cancer. This model is established by inoculating mouse mammary tumor cells with the human wild-type gene HER2 into C57BL/6 HER2 transgenic mice[15]. Particles with and without the targeting peptide were injected through the mouse lateral tail vein. Using FITC to label the peptide, the targeting peptide could be tracked and the localization in the tumor tissue was seen. Overall the transgenic mice received particles and all survived. Particles with pH responsive acetal crosslinking in the core are currently being developed and tested[16],[17]. It is expected that this stronger hydrophobic core will allow for more drug loading, and more importantly, more specific release in the more acidic tumor tissue. The therapeutic efficacies of a drug is improved by releasing it from a targeted polymer-drug system as the drug should better target and kill cancer cells in this case, while more healthy cells are spared from the harsh drugs. The superior transgenic model used confirms that this is possible. References:[1] “Breast Cancer Home Page - National Cancer Institute.” [Online]. Available: http://www.cancer.gov/cancertopics/types/breast. [Accessed: 20-Aug-2015].[2] Ma, J. & Jemal, A. Breast Cancer Metastasis and Drug Resistance. (2013). doi:10.1007/978-1-4614-5647-6[3] Blichert-Toft, M. et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. J. Natl. Cancer Inst. Monogr. 19–25 (1992).[4] Yu, M. K., Park, J. & Jon, S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics 2, 3–44 (2012).[5] Davis, M. E., Chen, Z. G. & Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771–782 (2008).[6] Meng, F., Zhong, Y., Cheng, R., Deng, C. & Zhong, Z. pH-sensitive polymeric nanoparticles for tumor-targeting doxorubicin delivery: concept and recent advances. Nanomedicine (Lond). 9, 487–99 (2014).[7] Gerweck, L. E., Vijayappa, S. & Kozin, S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol. Cancer Ther. 5, 1275–9 (2006).[8] Gerweck, L. & Seetharaman, K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res. 56, 1194–1198 (1996).[9] Yoo, H. S. & Park, T. G. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J. Control. Release 70, 63–70 (2001).[10] Li, G.-Z. et al. Investigation into thiol-(meth)acrylate Michael addition reactions using amine and phosphine catalysts. Polym. Chem. 1, 1196 (2010).[11] Nandivada, H., Jiang, X. & Lahann, J. Click Chemistry: Versatility and Control in the Hands of Materials Scientists. Adv. Mater. 19, 2197–2208 (2007).[12] Abbineni, G. & Modali, S. Evolutionary Selection new breast cancer cell-targeting peptides and phages with the cell-targeting peptides fully displayed on the major coat and their effects on actin dynamics during cell internalization. Mol. … 7, 1629–1642 (2010).[13] Gandra, N. et al. Bacteriophage bionanowire as a carrier for both cancer-targeting peptides and photosensitizers and its use in selective cancer cell killing by photodynamic therapy. Small 9, 215–21 (2013).[14] Gee, M., Upadhyay, R. & Bergquist, H. Human Breast Cancer Tumor Models: Molecular Imaging of Drug Susceptibility and Dosing during HER2/neu-targeted Therapy 1. Radiology 248, 925–935 (2008).[15] Wang, S. H. et al. Characterization of a Novel Transgenic Mouse Tumor Model for Targeting HER2 + Cancer Stem Cells. Int. J. Biol. Sci. 10, 25–32 (2014).[16] Bachelder, E. M., Beaudette, T. T., Broaders, K. E., Dashe, J. & Fre, J. M. J. Acetal-Derivatized Dextran : An Acid-Responsive Biodegradable Material for Therapeutic Applications. JACS Commun. 130, 10494–10495 (2008).[17] Park, T. et al. Photoswitchable Particles for On-Demand Degradation and Triggered Release. 3051–3057 (2013). Keywords: Drug delivery, medical application, targeting delivery, Cell modulation Conference: 10th World Biomaterials Congress, Montréal, Canada, 17 May - 22 May, 2016. Presentation Type: Poster Topic: Tissue targeting nanoparticles Citation: Doleyres Y, Cao Z, Wang S and Ma PX (2016). HER2+ peptide conjugated and pH responsive polyethylene glycol- poly(lactic-co-glycolic) acid (PEG-PLGA) nanoparticles tested in novel transgenic mouse tumor model. Front. Bioeng. Biotechnol. Conference Abstract: 10th World Biomaterials Congress. doi: 10.3389/conf.FBIOE.2016.01.02731 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 27 Mar 2016; Published Online: 30 Mar 2016. Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Yasmine Doleyres Zhengyi Cao Su He Wang Peter X Ma Google Yasmine Doleyres Zhengyi Cao Su He Wang Peter X Ma Google Scholar Yasmine Doleyres Zhengyi Cao Su He Wang Peter X Ma PubMed Yasmine Doleyres Zhengyi Cao Su He Wang Peter X Ma Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.